Merck KGaA v. Integra Lifesciences I — FDA Safe Harbor Covers All Pre-Clinical Research Reasonably Related to Drug Approval

Background

Integra Lifesciences and the Burnham Institute held five patents on RGD peptides — short protein sequences (Arg-Gly-Asp) that promote cell adhesion and play a role in angiogenesis, the growth of new blood vessels. Beginning in 1988, Merck KGaA, a German pharmaceutical company, funded research by Dr. David Cheresh at the Scripps Research Institute into whether RGD-containing compounds could be used to inhibit tumor angiogenesis and thereby fight cancer. During the 1990s, Cheresh’s lab used Integra’s patented RGD peptides in laboratory and animal studies exploring this hypothesis.

Integra sued Merck for patent infringement. Merck’s primary defense was the safe harbor provision enacted as part of the Hatch-Waxman Act in 1984: 35 U.S.C. § 271(e)(1) provides that it is not infringement to use a patented invention “solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs.” Merck argued that Cheresh’s research, aimed at developing potential drug candidates for eventual FDA review, was exactly what the safe harbor was designed to protect.

The Federal Circuit disagreed, holding the safe harbor applied only to research with a “direct link” to information actually submitted to the FDA. Because much of Cheresh’s preclinical work was exploratory — testing whether RGD compounds were even promising enough to warrant further development — the Federal Circuit said those studies fell outside the exemption. The Supreme Court reversed.

The Court’s Holding

Justice Scalia, writing for a unanimous Court, held that the safe harbor is broader than the Federal Circuit had recognized. The statute requires only that the use of the patented compound be “reasonably related” to developing information for an FDA submission — it does not require that the specific experiment produce data that is itself submitted to the FDA, nor does it require that the researcher have made a firm decision to file for FDA approval.

The Court explained that basic research into a compound’s mechanisms, dose responses, and toxicity profiles is an indispensable part of the drug development process, even when that research comes at an early stage where many candidates will ultimately be abandoned. Excluding such foundational research from the safe harbor would undermine the provision’s purpose: Congress enacted it to ensure that the patent system does not impede the development of generic and new drugs by making routine pre-clinical and clinical research legally risky.

The Court did note limits: the safe harbor does not cover research wholly disconnected from FDA regulatory processes, such as basic research aimed at advancing scientific knowledge without any realistic prospect of generating FDA submissions. But research with a plausible connection to an eventual FDA submission — even at the early exploratory stage — qualifies for protection.

Key Takeaways

• The § 271(e)(1) safe harbor applies to all uses of patented compounds that are reasonably related to generating information for FDA submission, not just uses that directly produce data submitted to the agency.
• Pre-clinical research — including exploratory animal studies and basic laboratory work — qualifies for the safe harbor even when the researcher has not yet committed to pursuing FDA approval for a specific compound.
• The Federal Circuit’s “direct link” requirement was rejected as too narrow; the proper standard is reasonable relation to the development of an FDA submission.
• The safe harbor does not extend to basic scientific research that has no realistic prospect of generating regulatory submissions.

Why It Matters

Drug development is an extraordinarily expensive, long, and uncertain process. A single approved drug may require testing hundreds of candidate compounds over many years before any reaches clinical trials. If each use of a patented research tool in this exploratory phase exposed researchers to infringement liability, pharmaceutical and biotech companies would face enormous legal risk in even the earliest stages of drug discovery. Merck v. Integra eliminated that risk by reading the safe harbor broadly.

The decision is particularly important for academic and government researchers, contract research organizations, and early-stage biotech companies that rely on patented biological materials and tools in preclinical work. It also has ongoing significance as the boundaries between “basic research” and “applied research with regulatory potential” continue to blur in fields like gene therapy, immunology, and precision medicine.